Targeting Disease at the Nuclear Pore
Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer and other major diseases.

XPOVIO® Now FDA-Approved in 2nd Indication

Our Commitment to Patients

SINE Technology

Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis.

Scientist doctor looking at sample in test tube

Pipeline

Our drug pipeline includes 4 unique investigational medicines targeting both hematologic malignancies and solid tumors.

Press Releases

July 1, 2020
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 24, 2020
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology

Upcoming Medical Conferences

Conference: European Hematology Association 2020 Virtual Annual Meeting
Location: Virtual
Date: June 11 – 21

Targeting Disease at the Nuclear PoreKaryopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer and other major diseases.